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Abstract
Cryptococcosis is an important systemic mycosis that threatens the lives of humans and
animals. The disease is caused by two species of the genus Cryptococcus: Cryptococcus neo‐
formans and Cryptococcus gattii. The diagnosis of cryptococcosis is made through micro‐
scopy, fungal culture followed by biochemical tests, and detection of the cryptococcal
capsular antigen (CrAg). Despite the existence of an established diagnostic protocol, the
search for new diagnostic tests is necessary due to the high incidence of the disease, with
estimates of approximately 1 million cases of cryptococcal meningitis per year and more
than 600,000 deaths in patients infected with human immunodeficiency virus (HIV), the
potential for C. gattii to cause the disease in immunocompetent individuals, and the dis‐
ease’s rapid worldwide dissemination. With the development of biotechnology, synthetic
peptides have opened up new possibilities as a source of pure epitopes and molecules for
the diagnosis of various diseases, based on the detection of circulating antibodies. Syn‐
thetic peptides can also be used for the development of vaccines. Studies on Leishmania‐
sis, Chagas disease, paracoccidioidomycosis, tuberculosis, and, more recently, on
cryptococcosis, among others, have shown that this approach shows potential for the ear‐
ly diagnosis of the disease, thus reducing the morbi-lethality of individuals affected by
this infection and ultimately changing their prognosis.
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1. Introduction
Cryptococcosis is an important systemic mycosis that threatens the lives of humans and
animals. It manifests primarily through respiratory system diseases and meningoencephalitis.
Cryptococcosis is among the emergent fungal infections with significant morbi-lethality, and
it is the fourth most frequent cause of opportunistic infection in human immunodeficiency
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virus (HIV)-positive patients. The disease is caused by two species of the genus Cryptococcus:
Cryptococcus neoformans and Cryptococcus gattii [1, 2].
C. neoformans has a worldwide distribution and is responsible for the high morbi-lethality in
immunocompromised individuals with AIDS. In contrast, infections with C. gattii are preva‐
lent in tropical and subtropical climate regions, and C. gattii primarily attacks immunocom‐
petent hosts. However, C. gattii has also emerged in countries with temperate climates, e.g.,
Canada (Vancouver) and the U.S. Northwest, which demonstrates that the fungus may adapt
to new environments and cause surges of infection in animals and humans [3–7].
Annually, AIDS-related cryptococcal meningitis is responsible for approximately 15% of the
mortality in these individuals [8]. Sub-Saharan Africa has the largest rate of coinfection with
Cryptococcus in these patients, and Cryptococcus is the most common cause of meningitis in
adults [9, 10]. Recent estimates indicate an incidence of approximately 10,000 cases per year of
cryptococcal meningitis in Latin America [11].
2. Etiological agents
C. neoformans and C. gattii are basidiomycetes in the asexual phase, appear as round cells,
though they are occasionally ovoid, are isolated or budding, and encased by a mucopolysac‐
charide capsule. C. neoformans is the anamorphic phase of Filobasidiella neoformans, and C.
gattii is the anamorphic phase of Filobasidiella bacillispora [12, 13].
C. neoformans was originally divided into two strands: var. neoformans (serotypes A, D, and a
hybrid AD) and var. gattii (serotypes B and C). In 2002, C. neoformans var. gattii was recognized
as a distinct species, C. gattii. Furthermore, previously observed phenotypic differences, newer
molecular studies, and the sequencing of the fungus’ genome were helpful to detect significant
genetic variations between serotypes A and D and to distinguish serotype A as a new strand,
C. neoformansvar. grubii [14, 15].
However, this classification becomes difficult, as significant divergences between serotypes
are frequently observed at the molecular level [16]. Serotype limits do not entirely coincide
with genetic groupings; therefore, serotyping is not regarded as a reliable technique for
differentiating strands of Cryptococcus [17].
A series of molecular studies were conducted, including polymerase chain reaction (PCR)
fingerprinting and amplified fragment length polymorphism (AFLP) analysis of the oroti‐
dine monophosphate pyrophosphorylase (URA5) gene and analysis of the phospholipase
(PLB1) gene by restriction fragment length polymorphism (RFLP). As a result of these analy‐
ses, the yeasts were classified into the following nine molecular types: VNI (AFLP1) and VNII
(AFLP1A and AFLP1B) (C. neoformans var. grubii, serotype A), VNIV (AFLP2) (C. neoformans
var. neoformans, serotype D), VNIII (AFLP3) (Hybrid, serotype AD), VNB (only one isolated in
Botswana) and VGI (AFLP4), VGII (AFLP6), VGIII (AFLP5) and VGIV (AFLP7), all correspond‐
ing to serotypes B and C, indicating that they evolved independently and in parallel [18–20].
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C. gattii genotype VGII was responsible for approximately 95% of the cryptococcosis infections
that occurred in the Island of Vancouver, Canada, and in the U.S. [3, 4, 21]. Genetic studies
with multilocus sequence typing (MLST), which uses the presence of virulence genes to
determine subgroups, have shown that the VGIIa and VGIIb subtypes are responsible for the
majority of cryptococcosis cases. Another subtype, VGIIc, which is also virulent, has emerged
in Oregon, U.S. and is now, together with subtype VGIIa, contributing to the rise of the disease
in that region [4, 22].
C. neoformans genotype VNI and C. gattii genotype VGI are regarded as the primary agents of
cryptococcosis worldwide. However, in Latin America, the distribution and occurrence of C.
gattii types differ from those in other continents [17, 19, 23, 24]. In Brazil, the C. gattii genotype
VGII type is responsible for infections in immunocompetent hosts in the Northern (N) and
Northeastern (NE) regions.
Genotype VGI is endemic in Australia and has also been described in Papua New Guinea,
Asia, and southern California. The VGIII and VGIV genotypes are found less frequently, with
the VGIII type isolated in the Ibero-American regions and in India and type VGIV recorded
in South Africa and in the U.S. [19, 25–29].
3. Natural history of the disease
Cryptococcosis is a systemic mycosis with a pulmonary gateway, which is caused by infection
with either C. neoformans or C. gattii. Infection is initiated after inhalation of the fungus’
infective propagules, which are the basidiospores, or desiccated yeasts, that are dispersed in
the environment [27, 30]. In the majority of cases, inhalation produces a self-limited asymp‐
tomatic pulmonary infection, which is dependent on the host’s immune response, the inocu‐
lum’s size, and the microorganism’s virulence. Residual focuses with viable fungal elements
can be established, and these can be reactivated after a number of years. At times, it may mimic
tuberculosis, with nodular lesions with no calcification and eventual cavitation. Other
presentations include a controlled mass similar to neoplasia, and at times, the disease manifests
as pneumonia that can evolve into acute respiratory failure. The pulmonary form is the second
most frequent form and attacks 35.7% of HIV-negative patients [31, 32].
Once in the lung, C. neoformans or C. gattii transit through the blood-brain barrier (BBB) to reach
the central nervous system (CNS), causing meningoencephalitis and, in the most serious forms
of the disease, brain cryptococcomas. The fungus shows high tropism in the CNS, which is
attributed to the optimal concentration of existing nutrients in the cerebrospinal fluid that can
be assimilated by the fungus (thiamine, glutamic acid, glutamine, dopamine, carbohydrates,
and minerals), as well as to the lack of complement system activity in the cerebrospinal fluid
(CSF) and the poor or absent inflammatory response activity of the brain tissue [33–35]. Del
Poeta et al. [1] recently found that despite the various mechanisms proposed to be responsible
for this neurotropism, it is still unknown as to how exactly this occurs during the infection in
humans. The C. gattii incubation period associated with outbreaks is known to be short. It is
believed that this strand can be more aggressive prior to its dissemination into the CNS. In the
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disseminated form, one can observe the development of cutaneous infections in the form of
papulae, pustules, or subcutaneous nodules. In addition, there are cases of primary cutaneous
infection with no dissemination, as well as infections in other organs [34, 36, 37].
4. Virulence factors
The pathogenic species of the genus Cryptococcus has a number of well-elucidated determi‐
nants of virulence. Some notable determinants include the ability to produce melanin,
extracellular enzymes, the capacity to survive and proliferate at 37°C (thermal tolerance), and
to escape oxidative damage caused by the host and the presence of a large polysaccharide
capsule [30, 38, 39].
The polysaccharide capsule is composed of 90 to 95% glucuronoxylomannan (GXM), 5%
galactoxylomannan (GalXM), and approximately 1% mannoproteins (MPs) [40, 41]. It is
regarded as one of the most important virulence factors for C. neoformans and C. gattii, and its
cell components accumulate in body fluids, thus serving as targets for diagnosis. The mecha‐
nism proposed to explain the contribution of the capsule to virulence is its capacity to inhibit
phagocytosis, inactivate components of the complement system, induce apoptosis, and
regulate cytokine synthesis. Inside the macrophages, Cryptococcus spp. releases and accumu‐
lates fragments of the polysaccharide, which is shown to be cytotoxic to the macrophage,
causing dysfunction or cell death [42–44].
5. Diagnosis of cryptococcosis
The laboratory diagnosis of cryptococcosis is based upon a number of principles: the demon‐
stration of the yeast in the clinical material, the isolation of the yeast in the culture followed
by biochemical tests for the final identification, anatomic-pathological examination, and
research into circulating antigens. Several biological materials may be used for the identifica‐
tion of fungal infection, e.g., serum, plasma, blood, tissue, and CSF, which is the major
biological material used for the diagnosis of cryptococcal infection in the CNS [45].
The direct research of the fungus can be accomplished using CSF, sputum, bronchial washing,
cutaneous-mucosal lesion pus, urine, macerates of biopsy tissue, prostatic secretion, blood,
and bone marrow biopsy specimens. Clinical samples analyzed with India ink indicate the
presence of the capsulated yeasts (Figure 1). This method is fast and low-cost but is not very
sensitive and cannot distinguish between species. Due to the high yeasts load found in samples
from AIDS patients, the sensitivity of this method may reach 80% for cryptococcal meningitis,
whereas in immunocompetent individuals, this sensitivity may be as low as 30–72% [46–48].
In addition, the success of this technique is dependent upon the expertise of the microbiologist,
and there are reports in the literature of false negatives in 20–30% of the results from infections
with C. neoformans or C. gattii due to a deficient capsule or the low fungal charge of the agent
in the CSF. This is primarily an issue with the initial cases, when the diagnosis is fundamental.
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Examination of C. neoformans or C. gattii in tissues is carried out with specific dyes, e.g.,
mucicarmine and silver [49].
Figure 1. Cyptococcus spp. cells with capsule from (A) cutaneous lesion and (B) sputum identified by India Ink (40×).
The culturing of Cryptococcus spp. serves to corroborate the diagnosis of the disease (Figure
2). The fungus grows well in various culture media that do not contain cycloheximide (blood
agar, Sabouraud agar, and brain–heart infusion agar). For cases of meningoencephalitis, the
CSF culture must be repeated 7 days after the beginning of treatment and fortnightly thereafter.
The cultures may remain positive for a long time, even over the course of treatment.
Figure 2. Cryptococcus culture in Sabouraud dextrose agar 2%.
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After obtaining the isolate, it is necessary to differentiate the species type for clinical and
epidemiological purposes [50–52]. Only C. gattii is resistant to canavanine and uses glycine as
a carbon source; thus, canavanine-glycine-bromothymol blue agar (CGB agar) was proposed
in 1982 and has been widely used in laboratories for distinguishing between C. gattii and C.
neoformans species [16, 53, 54]. However, a positive reaction in CGB agar is not sufficient for
definitively distinguishing the species as there have been reports of C. neoformans resistance
to high concentrations of canavanine [55, 56].
The production of urease is a biochemical test used to identify only the genus as both C.
gattii and C. neoformans are able to carry out hydrolysis of urea [57, 58]. The species C. neofor‐
mans and C. gattii are the only members of the genus that may produce melanin, thus showing
a brownish color in culture media with seed extracts, e.g., Vicia faba or Guizotia abyssinica. This
is due to the presence of tyrosine and chlorogenic acid in these seeds, which are oxidized by
phenoloxidase produced by yeast [59, 60]. Culture media that induce the production of
melanin are widely used in laboratories for the identification of yeast and differentiation of
Candida spp.
During infection, the capsular polysaccharides of C. neoformans and C. gattii solubilize in the
body fluids and can be detected and quantified with antibody-based assays. Detection of CrAg
(cryptococcal antigen) has been an effective tool for diagnosing cryptococcosis [61, 62].
Detection of CrAg in the serum and CSF by the latex agglutination test (CrAg-latex) or enzyme
immunoassays (EIA) has been used for more than 35 years [62]. The majority of comparative
studies use cultures as the gold standard. In individuals diagnosed with AIDS and meningitis,
the CrAg must always be evaluated, including cases in which the India ink assay cannot
identify the yeasts. One study showed that patients living in Uganda with cryptococcal
meningitis and HIV who had a negative yeast screening by the India ink assay tested positive
for CrAg detection by CSF [63].
The detection of the capsular antigen by agglutination of sensitized particles of latex (LA),
which until sometime ago was the immunological method with the most widespread clinical
use, may be accomplished in samples from the serum, urine, bronchoalveolar lavage, and CSF.
The serological reaction to latex agglutination (LA) is sensitive and specific, emphasizing titers
equal to or higher than 1/8 and being able to present cross reaction with the serum of patients
with rheumatoid arthritis [62, 64]. The enzyme-linked immunosorbent assay (ELISA) may
detect antigens from a cryptococcal infection earlier and at lower titers; however, it is time
consuming, expensive, and is laborious. Although CrAg-latex performs as well as EIA and
culture, its major limitations are that latex is a manual test and that the resulting interpretation
of it is subjective. CrAg-latex and EIA also require laboratory equipment and refrigeration of
reagents, making them inadequate for use in environments with minimal infrastructure [61].
The need for refrigeration drastically increases the cost of the test in places with limited
resources. Studies report that serological tests with CrAg-latex and EIA may show lower
sensitivity when used with strands of some genotypes of C. gattii. The rate of false-positive
examinations is lower than 1%; false positives are generally explained by technical issues,
existence of other infections (e.g., Trichosporon beigelii, Capnocytophaga canimorsus, and
Stomatococcus mucilaginosus), or contamination. False-negative results may occasionally be
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observed with early infections when there is a low fungal charge, with prozone phenomena,
and with poorly encapsulated organisms [62, 65].
Recently, a new sensitive, low-cost, fast, and non-laborious immunochromatographic assay
known as the lateral flow immunoassay (LFA) was made available for purchase for use in
serum, CSF, and urine [66]. This method has demonstrated good sensitivity for the detection
of cryptococcal antigen (CrAg), primarily in HIV-positive patients [27]. The World Health
Organization (WHO) has recommended the use of antigen detection using LFA for patients
infected with HIV who show low CD4 cells and are asymptomatic from a neurological
viewpoint [67]. This strategy enables the early identification of patients with a cryptococcal
disease in the subclinical stage [68]. It has been used in various studies as a form of screening
and diagnosis, thus easing its application to clinical practice. Nevertheless, reasonably good
results have been accomplished in multiple types of biological specimens, e.g., blood, CSF, and
urine [69].
6. Synthetic peptides
The concept of synthetic peptides and protocols for their artificial synthesis was introduced in
the early 20th century [70]. Since then, peptides have become increasingly important for
biochemistry, medicine, and biotechnology. In 1963, Bruce Merrifield described the develop‐
ment of solid-phase peptide synthesis, a technique that made the large-scale production of
synthetic peptides a reality. Since then, various studies with different sizes of synthetic
peptides have been reported [71].
In the early 1990s, with the development of biotechnology, recombinant antigens were widely
used in clinical diagnosis to detect specific antibodies. However, their use in diagnostic tests
presented some problems, such as low immunoreactivity compared with the corresponding
purified human antigens, laborious and expensive production, and variation in inter-assay
reactivity [72–76].
In this regard, synthetic peptides have opened up a new field and perspective as a source of
pure epitopes and molecules for the diagnosis of various infectious and noninfectious diseases
based on the detection of circulating antibodies and antigens and can also be used for the
development of vaccines [77]. Bioinformatics tools are widely used to predict antigenic and
immunogenic regions. These programs are capable of predicting B and T cells epitopes,
primarily by building on the known properties of amino acids, e.g., their hydrophilicity,
charge, flexibility, exposed surface area, and secondary structure [78–80].
Some factors must be taken into account when dealing with synthetic peptides. The first factor
to observe is whether the epitopic area is continuous or discontinuous because the amino acids
belonging to the epitope are often separated in the linear sequence and become juxtaposed
only when the antigen is in its native conformation. The second factor for observation is the
size of the epitope. When this field of study began, researchers worked with only small epitopes
as prior to the development of solid-phase peptide synthesis, one could not synthesize very
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large peptides. The very large peptides (>25–30 amino acids) are more expensive and difficult
to produce and also have lower yields. For these reasons, peptides of 10–15 amino acid residues
are usually recommended for the production and detection of antibodies [81–83].
The use of synthetic peptides for diagnostic tests confers several advantages, e.g., they are
innocuous, easy to store and transport, have a high level of reproducibility with low levels of
nonspecific reactions, and retain the possibility of changing the chemistry of the peptide by
inserting cysteine residues, fatty acids, or carrier proteins or even by incorporating post-
translational modifications, such as phosphorylation [84–86].
Over the past 20 years, several peptide sequences have been used to improve the sensitivity
and specificity of tests that use recombinant or native protein as antigens [87–93]. However,
the use of synthetic peptides as antigens has grown, with many diagnostic systems that are
based on synthetic peptides in production, with some being commercially available at the
present time. Some diagnostic tests that use synthetic peptides may already be part of the
routine clinical diagnosis of certain diseases that involve viruses, parasites, or autoimmune
diseases.
Some of the tests that are already available on the market include tests for Epstein–Barr virus,
which examines various epitopes on the capsid protein; hepatitis C virus, which includes
synthetic peptides that mimic its structural and nonstructural regions (NS4 and NS5); coro‐
navirus, which is composed of synthetic peptides derived from epitopes of the nucleocapsid
and spike proteins and can detect the presence of antibodies from human serum and plasma
specimens; Chlamydia trachomatis, which has three ELISA diagnostic tests available on the
market; and rheumatoid arthritis, with three generations of diagnostic tests based on the
detection of antibodies by synthetic peptides [94–97]. Despite the existence of various diag‐
nostic tests using synthetic peptides and the prevalence of studies reporting the use of synthetic
peptides for the diagnosis of various pathologies, particularly those of medical importance,
such as tuberculosis, Chagas disease, and leishmaniasis, little has evolved in this area with
respect to systemic mycoses [98–103].
Recent advances have been made in the search for more easily available immunodiagnostic
tests for fungal infections. Various methods with high specificity and sensitivity are still under
development, with a particular emphasis on the search for markers that are able to detect
infections at an early stage. In this regard, Caldini et al. [100] used synthetic peptides from the
gp75 Paracoccidioides brasiliensis antigen as an alternative diagnostic method for the detection
of paracoccidioidomycosis.
With regards to cryptococcosis, the search for new diagnostic tests is necessary due to the high
incidence of the disease, with estimates of approximately 1 million cases of cryptococcal
meningitis per year and more than 600,000 deaths in HIV-infected patients, the potential for
C. gattii to cause the disease in immunocompetent individuals, and its rapid worldwide
dissemination [8]. Therefore, controlling the disease is dependent on epidemiological control
of endemic areas coupled with the mapping of new cases and early diagnosis of the disease in
affected individuals.
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As previously mentioned, diagnostic methods based upon the detection of antibodies have
been developed and successfully applied to various other infectious diseases. The efficacy of
these methods is not impacted by the antigenic charge of the microorganism, which is
particularly relevant for the diagnosis of cryptococcosis, whose major diagnostic tests, LA and
LFA, are dependent on the charge of the antigen.
The early diagnosis of cryptococcosis is a challenge that science and the health system must
face as in most cases, the disease is diagnosed late, which results in significant morbidity and
mortality. Thus, efforts should be made toward finding a rapid, sensitive, and specific
diagnosis. In this sense, the identification of multiple immunogenic targets and the possibility
of synthesizing these artificial targets appear to be a promising alternative for the development
of more accurate tests for the diagnosis of systemic mycosis.
In this area, Martins et al. [104] have adopted an innovative strategy that combines the
technology of proteomics and bioinformatics, with the aim of identifying multiple immuno‐
genic targets for a diagnostic test for cryptococcosis. Linear B-cell epitopes of immunoreactive
proteins for Cryptococcus species were mapped using in silico analyses.
In the search for a faster and more specific test, Brandão et al. [105] tested various synthetic
peptides derived from immunoreactive proteins of Cryptococcusspp. Of these, six showed good
results, which became promising candidate antigens for future diagnostic tests. These six
peptides belonged to the proteins Hsp70, Sks2, GrpE, enolase, and two hypothetical proteins.
One of these, derived from Hsp70, showed 100% specificity and approximately 80% sensitivity.
Table 1 shows the specificity and sensitivity of diverse diagnostic methods for cryptococcosis.
Tests Sensitivity (%) Specificity (%) References
India ink 30–80 100 [46–48]
Culture 80 100 [106]
CrAg-LA 93–100 93–98 [62]
CrAg-EIA 93–100 93–98 [62]
CrAg-LFA 99–100 92–100 [106]
Synthetic peptides 55–79 90–100 [105]
CrAg, cryptococcal antigen; EIA, enzyme immunoassay; LFA, lateral flow assay; LA, latex agglutination
Table 1. Comparative performance of cryptococcosis diagnostic tests.
Hsp70 is a conserved protein that has been increasingly studied worldwide for its role in
various biological processes, including the interaction of Cryptococcusspp with host cells. Hsp
proteins have been characterized as dominant antigens in diverse models, including candi‐
diasis, aspergillosis, and histoplasmosis [107–110]. In cryptococcosis, the Hsp proteins have
been reported to be key antigens that are important for inducing the humoral response [104,
111–113]. These reports support the proposed use of epitopes from immunoreactive proteins,
e.g., Hsp70, as antigens in a diagnostic test for cryptococcosis.
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Higher diagnostic performance can be achieved with multi-epitope chimeric proteins. This
type of antigen becomes more attractive because it has more than one antigen-binding site,
thus multiplying the possibilities for increasing antigenicity. Brandão et al. demonstrated in a
theoretical model (in silico) that the combination of peptides in a single molecule is a good
strategy for improving the accuracy of a test; therefore, its use is of interest for the development
of new diagnostic tests [105, 114–118].
The use of this technology for the development of a diagnostic test capable of the early
identification of cryptococcosis and the possibility of building an effective vaccine for this
disease are essential for significant reduction in the morbidity and mortality of individuals
affected by this infection and may ultimately change their prognosis.
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